Lineage Cell Therapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $92.2M | $55.7M |
| FY2022 | — | $73.3M | $11.4M |
| FY2023 | — | $63.4M | $35.4M |
| FY2024 | — | $78.4M | $45.8M |
| FY2025 | — | $44.5M | $40.8M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $92.2M | $55.7M |
| FY2022 | — | $73.3M | $11.4M |
| FY2023 | — | $63.4M | $35.4M |
| FY2024 | — | $78.4M | $45.8M |
| FY2025 | — | $44.5M | $40.8M |